Pradaxa Lawsuit
Pradaxa (dabigatran etexilate mesylate) is a new blood thinning drug manufactured by Boehringer Ingelheim Pharmaceuticals. Pradaxa is in a class of drugs called Direct Thrombin Inhibitors, otherwise known as anticoagulants or blood thinners. Pradaxa was approved by the FDA in October of 2010 as a blood thinner that was superior to Warfarin because it allegedly required less monitoring. However, users of Warfarin who experience abdominal bleeding can counteract those side effects with Vitamin K, while there is no similar solution available to address Pradaxa bleeding. In just the first three months on the market, FDA received 307 reports of Pradaxa problems involving internal bleeding and other complications and within the first year, there were more than 260 Pradaxa reported deaths from internal bleeding. The Pradaxa bleeding deaths occurred between March 2008 and October 31, 2011, according to Boehringer Ingelheim.
Pradaxa Side Effects Include:
- Severe internal bleeding,
- Gastrointestinal bleeding,
- Brain hemorrhage,
- Kidney bleeding,
- Heart attack and
- Death
FDA Early Warning Notification
On December 7, 2011, FDA sent out an early warning notification evaluating the post-marketing reports of serious bleeding events in patients taking Pradaxa.
Were you injured from the serious side effects of taking Pradaxa? You may be entitled to compensation.